The Team
We have assembled a stellar team to guide this project to success.
Our business model is to retain an outstanding team of experts to guide the development. We will outsource the manufacturing, preclinical studies and human clinical trials. This approach enables us to acquire top-tier resources without investing in a large company infrastructure.
The managers of the company have had deep experience in developing biological products. We have retained individuals with first-tier experience in developing drugs for sexual dysfunction, bio-manufacturing, clinical development, regulatory affairs, management of clinical research organizations and finance.
| Terrance J. Bruggeman Chairman & CEO |
|
| W. Jay Treat, Ph.D. CTO & VP Manufacturing |
|
| Howard Asher Sr. Regulatory Advisor |
|
| Paul Fredlund, M.D. Clinical Development Consultant |
|
| Osama Ibrahim Ph.D. Sr. Advisor, VEGF Technology |
|
| Richard B. Stead, M.D. Sr. Clinical Advisor |
|
Our Medical Advisory Board consists of several of the best-known university research professors in the field of sexual dysfunction. Because of their stature, they are professors at leading universities: University of California San Francisco, Columbia University, Johns Hopkins Medical Institutions, and Northwestern University. All have conducted clinical research for the drugs currently on the market.
Further information about the team, our board, and the medical advisory board is available to qualified investors.
Request more information from Genevé Bio.